PA
ESPR

Perceptive Advisors’s Esperion Therapeutics ESPR Stock Holding History

Perceptive Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-200,000
Closed -$16.4M – 165
2015
Q2 		$16.4M Buy
+200,000
New +$19.6M 0.98% 26

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Perceptive Advisors's ESPR Position: Q2 2018 in Review

Perceptive Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 10,769 shares — an estimated $779K sold.

Perceptive Advisors first reported a position in ESPR in Q4 2014 and held it in 5 quarters. The position peaked at $12.2M in Q4 2014. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

  • Perceptive Advisors reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Perceptive Advisors sold 10,769 Esperion Therapeutics shares in Q2 2018, an estimated $779K.
  • Perceptive Advisors first reported a position in Esperion Therapeutics in Q4 2014 and held it in 5 quarters.
  • Perceptive Advisors's Esperion Therapeutics position peaked at $12.2M in Q4 2014.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.